Thus, MYCN-unamplified SK-N-AS and MYCN-amplified SK-N-DZ NB xenografts respond to FZD2 blockade by downregulation of β-catenin-dependent signaling and concurrent upregulation of β-catenin-independent signaling activities. The gene discussed is FZD2; the disease is neuroblastoma.